Monument Therapeutics

Monument Therapeutics is a UK-based biotechnology company founded in 2019, specializing in precision neuroscience drug development. Headquartered in Macclesfield, Cheshire, the company focuses on using proprietary digital biomarkers to match patients with treatments for central nervous system disorders, particularly in psychiatry and neurology. Monument Therapeutics aims to address challenges in drug development by applying digital biomarkers for patient stratification, similar to approaches used in precision medicine for cancer. The company is developing clinical-stage therapeutics that combine digital biomarkers with novel formulations of established CNS-active small molecules. Key projects include MT1988, a fixed-dose combination drug for cognitive impairment associated with schizophrenia, and MT1980, a new therapeutic agent for neuroinflammatory conditions. Monument Therapeutics serves the biotechnology and pharmaceutical sectors, providing cognitive assessments to enhance drug response and trial success, while supporting partners in developing treatments for high-unmet-need areas.